Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for ...
NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...
In einem turbulenten Marktumfeld ist die Aktie von Mainz Biomed (NASDAQ: MYNZ) BV auf ein 52-Wochen-Tief von 0,18 US-Dollar gefallen. Dieser deutliche Rückgang spiegelt eine drastische Veränderung im ...
Benzinga Finance on MSN4d
Mainz Biomed $MYNZ & Thermo Fisher Partner On Next-Gen Colorectal Cancer Screening ProductMines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...
Mainz Biomed Announces Stock Split. BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...
Emittent / Herausgeber: Mainz BioMed N.V. / Schlagwort(e): Sonstiges Mainz Biomed gibt Aktienzusammenlegung bekannt 29.11.2024 / 14:45 CET/CEST Für den Inhalt der Mitteilung ...
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in ...
Fintel on MSN9d
HC Wainwright & Co. Downgrades Mainz Biomed N.V. (MYNZ)Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...
During the Nasdaq Listing Qualifications Hearing, Psyence Biomed presented a comprehensive plan to regain and maintain compliance with the exchange’s continued listing requirements, including ...
The Nasdaq Hearings Panel has given Psyence Biomed until December 31, 2024, to comply with the minimum bid price, market value of publicly held shares, and stockholders' equity requirements. During ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback